Journal
Nature Communications
Publication Date
3-20-2024
Volume
15
Issue
1
First Page
2503
Document Type
Open Access Publication
DOI
10.1038/s41467-024-46811-w
Rights and Permissions
Bulle, A., Liu, P., Seehra, K. et al. Combined KRAS-MAPK pathway inhibitors and HER2-directed drug conjugate is efficacious in pancreatic cancer. Nat Commun 15, 2503 (2024). https://doi.org/10.1038/s41467-024-46811-w This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Recommended Citation
Bulle, Ashenafi; Liu, Peng; Seehra, Kuljeet; Bansod, Sapana; Chen, Yali; Zahra, Kiran; Somani, Vikas; Khawar, Iftikhar Ali; Chen, Hung-Po; Dodhiawala, Paarth B; Li, Lin; Geng, Yutong; Mo, Chia-Kuei; Mahsl, Jay; Ding, Li; Govindan, Ramaswamy; Davies, Sherri; Mudd, Jacqueline; Hawkins, William G; Fields, Ryan C; DeNardo, David G; Held, Jason M; Grierson, Patrick M; Wang-Gillam, Andrea; Ruzinova, Marianna B; Lim, Kian-Huat; and et al., "Combined KRAS-MAPK pathway inhibitors and HER2-directed drug conjugate is efficacious in pancreatic cancer." Nature Communications. 15, 1. 2503 (2024).
https://digitalcommons.wustl.edu/oa_4/3577
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
